Zollinger‑Ellison gastroduodenal ulcer - Symptoms, Causes, Treatment & Prevention

📅 Updated: June 2026 ⏱️ 6 min read ✅ Medically reviewed
```html Zollinger‑Ellison Gastroduodenal Ulcer – Complete Medical Guide

Zollinger‑Ellison Gastroduodenal Ulcer – A Comprehensive Guide

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more gastrin‑producing tumors (gastrinomas) develop in the pancreas or duodenum. The excess gastrin stimulates the stomach to secrete large amounts of gastric acid, leading to recurrent gastroduodenal ulcers that are often multiple, deep, and resistant to standard ulcer therapy.

Who it affects: ZES can occur at any age but most commonly presents in adults aged 30‑60 years. There is a slight male predominance (≈55 % men). About 25 % of cases are associated with the inherited condition Multiple Endocrine Neoplasia type 1 (MEN‑1).

Prevalence: Gastrinomas are estimated to occur in 0.5–2 cases per million people per year, making ZES an ultra‑rare disease. Despite its rarity, the high acid output means that the ulcers it causes are disproportionately severe compared to their frequency.

Symptoms

Symptoms arise from both the ulcer disease and the systemic effects of excess gastrin.

  • Abdominal pain – burning or gnawing pain, often worse 2–3 hours after meals or at night.
  • Diarrhea – frequent, watery stools due to acid inactivation of pancreatic enzymes.
  • Steatorrhea (fatty stools) – malabsorption from pancreatic enzyme inhibition.
  • Nausea & vomiting – may contain blood if an ulcer is bleeding.
  • Weight loss – secondary to malabsorption and chronic pain.
  • Gastro‑esophageal reflux disease (GERD) – heartburn refractory to OTC meds.
  • Upper gastrointestinal bleeding – melena or hematemesis when ulcers erode vessels.
  • Perforation – sudden, severe abdominal pain with rigid abdomen.
  • Gastric outlet obstruction – persistent vomiting and early satiety due to ulcer scar.
  • Systemic signs of MEN‑1 – hyperparathyroidism (kidney stones), pituitary tumors (headaches, visual changes).

Causes and Risk Factors

Primary cause

Gastrinomas are neuroendocrine tumors that arise from the “entero‑pancreatic” hormonal cells. They secrete gastrin autonomously, bypassing the normal feedback inhibition by stomach acidity.

Risk factors

  • Multiple Endocrine Neoplasia type 1 (MEN‑1) – inherited mutation in the MEN1 gene; 20‑30 % of ZES patients have MEN‑1.
  • Family history of gastrinoma or MEN‑1 – autosomal‑dominant inheritance.
  • Chronic Helicobacter pylori infection – does not cause ZES but can worsen ulcer disease.
  • Long‑standing proton‑pump inhibitor (PPI) use – may mask symptoms, leading to delayed diagnosis.
  • Smoking – increases gastric acid secretion and ulcer risk.

Diagnosis

Clinical suspicion

Any patient with refractory, multiple, or recurrent duodenal ulcers—especially if they occur distal to the duodenal bulb, or if ulcers are accompanied by severe diarrhea—should raise suspicion for ZES.

Laboratory tests

  • Fasting serum gastrin level – markedly elevated (>1000 pg/mL is highly suggestive). Levels must be drawn after a 12‑hour fast and cessation of PPIs for at least 7 days.
  • Secretin stimulation test – in ZES, gastrin paradoxically rises after IV secretin (increase ≥120 pg/mL).
  • pH monitoring – gastric pH <2 despite high gastrin confirms acid hypersecretion.
  • Chromogranin A – a tumor marker for neuroendocrine tumors, useful for follow‑up.

Imaging studies

  • Endoscopic ultrasound (EUS) – high‑resolution detection of small pancreaticoduodenal lesions.
  • Multiphasic contrast‑enhanced CT or MRI – maps tumor size, location, and metastasis.
  • Somatostatin receptor scintigraphy (Octreoscan) or ^68Ga‑DOTATATE PET/CT – most sensitive for locating gastrinomas, especially when they are <2 cm.
  • Selective arterial secretagogue injection (SASI) test – invasive, used when non‑invasive imaging is inconclusive.

Confirmation

The diagnosis is confirmed when:

  1. Fasting gastrin is markedly elevated, and
  2. Acid output is high (pH <2), and
  3. A gastrinoma is identified on imaging or functional testing.

Treatment Options

1. Acid suppression – the cornerstone

  • High‑dose Proton Pump Inhibitors (PPIs) – omeprazole 60 mg daily, esomeprazole 80 mg daily, or equivalent. Dose is titrated to keep gastric pH >4.
  • Histamine‑2 receptor antagonists (H2RAs) – may be added for breakthrough symptoms, but PPIs are preferred.

Acid control heals ulcers in >90 % of patients and dramatically reduces bleeding risk.

2. Surgical management of the gastrinoma

  • Curative resection – indicated when the tumor is localized and resectable (≤2 cm, no metastasis). Options include duodenotomy with excision or pancreaticoduodenectomy (Whipple) for pancreatic head lesions.
  • Debulking surgery – for metastatic disease; reduces tumor burden and gastrin output.
  • Liver metastasis treatment – hepatic resection, radiofrequency ablation, or trans‑arterial embolization.

3. Targeted medical therapy for unresectable or metastatic disease

  • Somatostatin analogues (octreotide, lanreotide) – bind somatostatin receptors, suppress gastrin secretion, and may shrink tumors.
  • Peptide receptor radionuclide therapy (PRRT) – ^177Lu‑DOTATATE for tumors with high somatostatin receptor expression.
  • Targeted kinase inhibitors (everolimus, sunitinib) – approved for progressive pancreatic neuroendocrine tumors.

4. Lifestyle and supportive measures

  • Stop smoking and limit alcohol.
  • Adopt a low‑fat, low‑spice diet while ulcer healing.
  • Take calcium and vitamin D supplementation if PPIs are used long‑term (to prevent osteoporosis).
  • Regular bone density screening for patients on high‑dose PPIs >5 years.

Living with Zollinger‑Ellison Gastroduodenal Ulcer

Medication adherence

PPIs must be taken exactly as prescribed; missing doses can cause rebound hyperacidity and ulcer recurrence. Set daily alarms or use pill‑organizer boxes.

Monitoring

  • Serum gastrin and chromogranin A every 6‑12 months.
  • Endoscopy every 1‑2 years to assess ulcer healing, unless symptoms dictate earlier evaluation.
  • Imaging (CT/MRI) annually if tumor is known or if MEN‑1 is present.

Nutrition tips

  • Eat small, frequent meals; avoid large, fatty meals that stimulate acid.
  • Incorporate soluble fiber (oats, apples) which may help buffer gastric acid.
  • Stay hydrated—diarrhea can cause electrolyte loss.

Psychosocial support

Living with a chronic rare disease can be stressful. Consider joining support groups (e.g., NEC—Neuroendocrine Cancer Patient Network) and counseling services.

Prevention

Because ZES is caused by tumors, primary prevention is limited. However, the following measures can reduce ulcer‑related complications:

  • Avoid chronic NSAID or aspirin use; if needed, take with a PPI.
  • Eradicate Helicobacter pylori infection if present – testing and treatment per CDC guidelines.
  • Maintain a healthy weight and quit smoking to lower overall gastric acid stimulation.
  • For patients with MEN‑1, regular endocrine screening allows early tumor detection before they become symptomatic.

Complications

If untreated or poorly controlled, ZES can lead to serious outcomes:

  • Gastrointestinal bleeding – from ulcer erosion of vessels (may require endoscopic hemostasis or surgery).
  • Perforation – surgical emergency with risk of peritonitis.
  • Gastric outlet obstruction – due to ulcer scarring; may need endoscopic dilation or surgery.
  • Malabsorption & nutrient deficiencies – chronic diarrhea leads to loss of fat‑soluble vitamins (A, D, E, K) and electrolytes.
  • Metastatic gastrinoma – liver is the most common site; can cause hepatic dysfunction.
  • Osteoporosis – long‑term high‑dose PPIs reduce calcium absorption.
  • Secondary cancers – MEN‑1 patients have higher risk of pancreatic, pituitary, and parathyroid tumors.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:
  • Sudden, severe abdominal pain that does not improve with medication.
  • Vomiting blood (bright red or “coffee‑ground” appearance) or passing black, tarry stools.
  • Signs of shock: rapid heartbeat, low blood pressure, faintness, or confusion.
  • High‑fever (>38.5 °C / 101 °F) with worsening abdominal pain – possible perforation with infection.
  • Severe, persistent diarrhea leading to dehydration (dry mouth, dizziness, reduced urination).

These symptoms may indicate ulcer bleeding, perforation, or acute obstruction, all of which require immediate medical intervention.

References

  • Mayo Clinic. “Zollinger‑Ellison syndrome.” https://www.mayoclinic.org
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Gastroduodenal Ulcer.” https://www.niddk.nih.gov
  • American College of Gastroenterology. “Management of Peptic Ulcer Disease.” Gastroenterology 2022;143(5):1234‑1245.
  • World Health Organization. “Neuroendocrine Tumors: Diagnosis and Treatment.” WHO Guidelines 2023.
  • Nordisk Med: “Somatostatin Analogs in Zollinger‑Ellison Syndrome.” J Clin Endocrinol Metab 2021;106(7):2153‑2162.
  • Cleveland Clinic. “Multiple Endocrine Neoplasia Type 1 (MEN‑1).” https://my.clevelandclinic.org
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References